When Wes Streeting endorsed Andy Burnham last week, the move was read primarily as a political calculation, a health secretary backing the candidate most likely to succeed, and positioning himself for influence in whatever follows. That reading is not wrong. But it misses something. The decision Burnham now faces about who occupies No 11 is, for the NHS, one of the most consequential of his premiership before it has even begun.

The debate about Streeting versus Ed Miliband is being framed largely through the lens of economic ideology, union relations, and investor confidence. All of that matters. But the NHS dimension is specific and substantial, and it has received less attention than it deserves.

Streeting, as health secretary, was an active and often contentious force in NHS reform. He pushed for greater private sector involvement in clearing waiting lists, championed productivity metrics, and held a broadly Blairite view that the source of care mattered less than its speed and quality. NHS leaders who worked alongside him found him direct and at times impatient with institutional inertia. He was not universally popular, but he was engaged. He understood the system's operating pressures with the granularity that comes from time spent inside them.

Miliband has no comparable health policy record. His instincts are more statist, his relationships with the unions warmer, and his political identity shaped far more by energy and climate than by public service reform. That is not a disqualification, chancellors are not health secretaries, but it is relevant. A Treasury under Miliband would likely be more receptive to workforce demands and more sceptical of private sector expansion in health. It might also be more cautious about the commercial health-tech partnerships that NHS England has been developing, and less inclined to push NHS productivity through market mechanisms.

For health-tech and life sciences businesses that spent much of the last year navigating procurement frameworks, AI regulation, and NHS partnership structures, the identity of the chancellor is not an abstract concern. Capital budgets, the pace of digital transformation, the treatment of data infrastructure investment, the risk appetite for procurement reform, these are Treasury questions as much as DHSC ones. A Miliband Treasury might invest more in the NHS; it might also invest differently, and more slowly where commercial models are involved.

The workforce dimension is where the stakes are sharpest. NHS pay negotiations, consultant contract disputes, and the continuing pressure on nursing and allied health professional pipelines all flow eventually to the spending review settlement. Unison's endorsement of Miliband is partly a signal about what unions expect that settlement to look like. But public sector pay is not simply a question of generosity, it is a question of what the fiscal framework allows, and Miliband's reputation for growth scepticism, fairly or not, has made some in the NHS finance community uneasy.

Burnham's own NHS instincts are well-documented. As health secretary under Gordon Brown, he was the architect of the first serious moves toward integrating health and social care. His devolution model in Greater Manchester, which gave Integrated Care Boards a local political anchor, was a genuine structural experiment. He arrives in No 10 with a clearer health policy vision than most incoming prime ministers.

The question is whether that vision will be resourced and supported by a chancellor who shares its logic, or complicated by one who does not. That is the tension now playing out in the union endorsements, the backroom negotiations, and the careful positioning of potential rivals. For NHS leaders, it is worth watching with the same attention usually reserved for a spending review.

The chancellor does not run the health service. But they determine what running it is allowed to cost.